NEW YORK (TheStreet) -- Aegerion Pharmaceuticals (AEGR) surged in after-hours trading Tuesday after the company reported second-quarter earnings that beat analysts' expectations and guided full-year Juxtapid sales above the consensus estimate.
Aegerion reported a loss of 33 cents a share, narrower than the consensus estimate of a loss of 41 cents a share. Juxtapid sales totaled $36 million, which beat analysts' estimate of $35.4 million.
The company also guided full-year sales of Juxtapid in the lower end of its previously stated range of $180 million to $200 million, while analysts expect total revenue of $173.07 million for the fiscal year.
The stock was up 11.37% to $34.10 at 4:54 p.m.
Separately, TheStreet Ratings team rates AEGERION PHARMACEUTICALS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:
"We rate AEGERION PHARMACEUTICALS INC (AEGR) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself."
You can view the full analysis from the report here: AEGR Ratings Report
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.